目的 探讨西黄丸联合贝伐珠单抗注射液治疗晚期结直肠癌的治疗效果。方法 选取2021年8月—2023年8月保定市第一医院收治的晚期结直肠癌患者86例，参照随机数字表法分为对照组（43例）和治疗组（43例）。对照组患者静脉滴注贝伐珠单抗注射液，5 mg/(kg?d)，持续时间90 min以上，1次/2周。治疗组患者在对照组的基础上口服西黄丸，3 g/次，2次/d。两组均治疗8周。比较两组的临床疗效、Karnofsky（KPS）评分、生活质量（QOL）评分和血清肿瘤标志物水平。结果 相较于对照组，治疗组患者的客观缓解率、疾病控制率较高（P＜0.05）。治疗后，两组的KPS、QOL评分均显著升高（P＜0.05），且治疗组KPS、QOL评分明显高于对照组（P＜0.05）。治疗后，两组血清糖类抗原19-9（CA19-9）、糖类抗原125（CA125）、癌胚抗原（CEA）、糖类抗原242（CA242）水平均显著降低（P＜0.05），且治疗组血清肿瘤标志物水平均显著低于对照组（P＜0.05）。结论 西黄丸联合贝伐珠单抗注射液治疗晚期结直肠癌疗效确切，可改善患者生存质量，降低肿瘤标志物水平。

Objective To explore the therapeutic effect of Xihuang Pills combined with Bevacizumab Injection in treatment of advanced colorectal cancer. Methods Patients (86 cases) with advanced colorectal cancer in Baoding NO. 1 Hospital from August 2021 to August 2023 were divided into control and treatment groups according to the random number table method, and each group had 43 cases. Patients in the control group were iv administered with Bevacizumab Injection, 5 mg/(kg?d), infusion duration of more than 90 min, once per two weeks. Patients in the treatment group were po administered with Xihuang Pills on the basis of the control group, 3 g/time, twice daily. Patients in two groups were treated for 8 weeks. The clinical efficacies, QOL scores, KPS scores, and serum tumor marker levels in two groups were compared. Results Compared with the control group, ORR and CBR of the treatment group were higher (P < 0.05). After treatment, KPS scores and QOL scores in two groups were significantly increased (P < 0.05), and KPS scores and QOL scores in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the serum levels of CA19-9, CA125, CEA, and CA242 in two groups were significantly decreased (P < 0.05), and the serum tumor marker levels in treatment group were significantly lower than those in control group (P < 0.05). Conclusion Xihuang Pills combined with Bevacizumab Injection is effective in treatment of advanced colorectal cancer, can improve the quality of life of patients, reduce the level of tumor markers.

R979.1

保定市科技计划项目（2241ZF034）